Cytokine Status of Women With Postmenopausal Osteoporosis in Dynamics of Treatment With Alendronat

Abstract

The aim of work was to study blood serum concentrations of tumor necrosis factor alpha (TNF-α), interleukins (IL) -1β, -6, -10, -17A, osteoprotegerin (OPG) and receptor activator of nuclear factor κB ligand (RANKL) in dynamics of alendronic acid-based treatment in women with postmenopausal osteoporosis with. 136 women with postmeno- pausal osteoporosis were examined in dynamics of treatment with alendronate. Treatment duration was 12 months. TNF-α, IL-1β, IL-6, IL-10, IL-17A, OPG and RANKL serum concentrations were studied in all patients before and after treatment. Molecular genetic studies included real-time PCR testing of ESR1 gene rs2234693 polymorphisms and IL-6 gene rs1800795 one. Women with postmenopausal osteoporosis had increased serum IL-1β and IL-6 concentra- tions before and after therapy (p<0.05), as well as RANKL before treatment (p=0.033). The dynamics of OPG content (p=0.013), as well as OPG/RANKL index (p=0.010) decrease was noted during the therapy course. TT genotype of rs2234693 polymorphism of ESR1 gene in women with postmenopausal osteoporosis is associated with increased RANKL production and decreased OPG/RANKL ratio both before and after treatment (p<0.05). Women with GG geno- type of rs1800795 polymorphism of IL-6 gene are characterized by consistently increased levels of IL-6 (before and after treatment), as well as IL-17A before starting therapy (p<0.05). It is reasonable to use the obtained results for development of postmenopausal osteoporosis personalized treatment regimens development.